FDA delays Sarepta's Duchenne gene therapy decision by a month
The FDA delayed its decision whether to grant accelerated approval to Sarepta Therapeutics’ gene therapy for Duchenne muscular dystrophy, pushing it back about one month …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.